Skip to main content
OpenTrials
Completed

NCT Number: NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Respiratory Syncytial Virus Infections Infections Mononegavirales Infections Paramyxoviridae Infections Pneumovirus Infections RNA Virus Infections Virus Diseases

Age range

Up to 24 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital General De Ninos Pedro De Elizalde, Buenos Aires, Argentina

Loading trial locations.

About this study

A randomized, double-blind, palivizumab-controlled, multi-center, multi-national trial conducted during 2 Northern Hemisphere RSV seasons with an intervening season in the Southern Hemisphere. Each child only participated during a single RSV season. Approximately 6,600 children at risk for serious RSV disease were to be randomized in a 1:1 ratio to receive either 15 mg/kg of palivizumab or motavizumab by IM injection every 30 days for a total of 5 doses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 24 months of age or younger at randomization (child must be randomized on or before his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of prematurity requiring medical intervention/management (i.e., supplemental oxygen, bronchodilators, or diuretics) within 6 months before randomization

OR:

  • 35 weeks gestational age or less at birth and 6 months of age or younger at randomization (children were to be randomized on or before his/her 6-month birthday)

Exclusion criteria

  • Hospitalization at the time of randomization (unless discharge was anticipated within 10 days)
  • Mechanical ventilation or other mechanical support (including continuous positive airways pressure [CPAP])
  • Life expectancy < 6 months
  • Active RSV infection (a child with signs/symptoms of respiratory infection must have had negative RSV testing)
  • Known renal impairment
  • Known hepatic dysfunction
  • Chronic seizure or evolving or unstable neurologic disorder
  • Congenital heart disease [CHD] (children with uncomplicated CHD [e.g., patent ductus arterious (PDA), small septal defect] and children with complicated CHD that were currently anatomically and hemodynamically normal could be enrolled)
  • Known immunodeficiency
  • Mother with HIV infection (unless the child has been proven to be not infected)
  • Known allergy to Ig products
  • Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization
  • Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)
  • Previous receipt of RSV vaccines
  • Participation in other investigational drug product studies

Treatment and study plan

motavizumab (MEDI-524)

Biological

Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Other names: MEDI-524

Palivizumab

Biological

Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Other names: Synagis

Primary outcomes

  1. Incidence of RSV Hospitalization (Includes Deaths by RSV)

    Time frame: Days 0 - 150

    RSV hospitalization was defined as 1) a respiratory hospitalization with a positive RSV test (primary), 2) a new onset of lower respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial), or 3) death demonstrated to have been caused by RSV (by autopsy or clinical history and virologic evidence).

  2. Number of Participants Reporting Any Adverse Events (AEs)

    Time frame: Days 0 - 150

    Number of participants reporting one or more AEs

  3. Number of Participants Reporting Any Related AEs

    Time frame: Days 0 - 150

    Number of participants reporting one or more AEs considered related to study drug by the investigator

  4. Number of Participants Reporting Any Serious Adverse Events (SAEs)

    Time frame: Days 0 - 150

    Number of participants reporting one or more SAEs

  5. Number of Participants Reporting Any Related SAEs

    Time frame: Days 0 - 150

    Number of participants reporting one or more SAEs considered related to study drug by the investigator

  6. Number of Participants Reporting AEs by Highest Severity Grade

    Time frame: Days 0 - 150

    Adverse events events were graded by severity; Level 1, 2, 3, or 4

  7. Number of Participants Who Discontinued Study Drug Due to AEs

    Time frame: Days 0 - 150

  8. Number of Participants Who Died

    Time frame: Days 0 - 150

  9. Number of Participants Reporting Changes in Vital Signs From Baseline

    Time frame: Days 0 - 150

    Vital signs that were in a higher toxicity grade than observed at baseline were to be recorded as AEs

Secondary outcomes

  1. The Incidence of Outpatient Medically-attended Lower Respiratory Illness (LRI)

    Time frame: Day 0 - 150

    LRI was defined as an event of bronchiolitis or pneumonia or the occurance of a lower tract infectious illness as determined by the PI based on medical history, signs, and symptoms.

  2. The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups

    Time frame: Days 0 - 150

    The RSV-specific LRI was defined as an outpatient medically-attended LRI associated with a positive RSV test and was not inclusive of events that required hospitalization.

  3. The Incidence of Medically-attended Otitis Media (OM) Infections

    Time frame: Days 0 - 150

    Otitis media (OM) was to be recorded as the diagnosis if the following terms were used by the medical care provider: acute OM, acute tympanic membrane (TM) perforation, bulging TM, red TM with fever, OM with effusion, or middle ear effusion. A new episode was defined as a physician-diagnosed OM in either ear after a normal middle ear exam of the ear in question or an episode of acute OM greater than or equal to 21 days after resolution of the previous episode. A diagnosis of persistent middle ear effusion was not to be recorded as a new OM event.

  4. The Frequency of Prescribed Antibiotics for Medically-attended LRI

    Time frame: Days 0 - 150

    The average number of presciptions per event per subject was summarized for each treatment group.

  5. The Frequency of Prescribed Antibiotics for Medically-attended OM Infections

    Time frame: Days 0 - 150

    The average number of presciptions per event per subject was summarized for each treatment group.

  6. The Number of Participants With Anti-motavizumab Antibodies

    Time frame: Day 0 - 120

    Detection of anti-motavizumab antibodies was defined as a titer with a dilution value equal to or greater than 1:10.

  7. The Serum Concentrations of Motavizumab at Day 0

    Time frame: Day 0

    Mean serum concentrations of motavizumab at Day 0

  8. The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 1

    Time frame: 30 days post Dose 1

    Mean serum concentrations of motavizumab at 30 days post Dose 1

  9. The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 2

    Time frame: 30 days post Dose 2

    Mean serum concentrations of motavizumab at 30 days post Dose 2

  10. The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 3

    Time frame: 30 days post Dose 3

    Mean serum concentrations of motavizumab at 30 days post Dose 3

  11. The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 4

    Time frame: 30 days post Dose 4

    Mean serum concentrations of motavizumab at 30 days post Dose 4

Sponsors and collaborators

Lead sponsor

MedImmune LLC

Industry

Registry information

Official study title

A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

Important dates

Study start
2004
Primary completion
2006
Study completion
2006
First posted
Aug 12, 2005
Registry last updated
Aug 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.